乳腺癌双采集18F-FDG PET的血流与代谢:与肿瘤表型及新辅助化疗反应的相关性
本前瞻性研究纳入150例有NAC指征的乳腺癌女性,用单次18F-FDG双采集PET同时评估肿瘤血流(BF)与SUVmax。基线SUVmax与肿瘤侵袭性生物学标志相关,BF仅与肥胖相关;SUVmax变化预测pCR优于BF变化。
要点
- 基线SUVmax与三阴性亚型等侵袭性标志相关,BF仅与肥胖相关。
- SUVmax变化预测pCR的AUC在三阴性、HER2阳性、luminal亚型分别为0.82、0.65、0.90。
- BF仅在HER2阳性亚型大幅下降(-58.7%±30.0%),支持曲妥珠单抗抗血管效应。
核心结论
- 在评估的两种癌症生物学标志中,肿瘤葡萄糖代谢降低比肿瘤BF降低更能准确预测不同乳腺癌亚型的pCR。
研究设计与样本
- 前瞻性研究纳入150例有NAC指征的乳腺癌女性。
- 注射18F-FDG时行2分钟胸部动态PET采集,90分钟后行延迟静态PET采集。
- 肿瘤BF用验证过的一首过模型从动态采集计算,SUVmax从延迟采集计算。
- 第一周期NAC后重复双采集以测量BF和SUVmax的早期变化。
主要发现
- 基线SUVmax与BF呈弱相关(r=0.22;P=0.006)。
- 高基线SUVmax与所有肿瘤侵袭性生物学标志相关,包括三阴性乳腺癌亚型(P<0.0001)。
- 高基线BF仅与肥胖相关(P=0.002)。
- SUVmax变化(均值-44.6%±27.4%)随Scarff-Bloom-Richardson分级、HER2过表达和激素受体表达缺失而不同(P=0.04、P<0.001、P=0.01)。
- BF变化(均值-26.9%±54.3%)仅在HER2阳性亚型大幅下降(-58.7%±30.0%)。
关键数值与推荐
- SUVmax变化预测pCR的AUC:三阴性0.82、HER2阳性0.65、luminal 0.90。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early changes in tumor glucose metabolism (SUVmax) and in tumor blood flow (BF) have been evaluated separately for monitoring breast cancer response to neoadjuvant chemotherapy (NAC). This study used a single 18F-FDG dual-acquisition PET examination to simultaneously assess these two imaging features and to determine whether they correlate with the same pretherapy tumor phenotypic features and whether they are comparable or complementary in predicting pathologic complete response (pCR). Methods: This prospective study included 150 women with breast cancer and an indication for NAC. A 2-min chest-centered dynamic PET acquisition was performed at the time of 18F-FDG injection, followed by a delayed static PET acquisition 90 min later. Tumor BF was calculated from the dynamic acquisition using a validated first-pass model, and tumor SUVmax was calculated from the delayed acquisition. This dual acquisition was repeated after the first cycle of NAC to measure early changes in tumor BF and SUVmaxResults: A weak correlation was found between SUVmax and BF at baseline (r = 0.22; P = 0.006). A high baseline SUVmax was associated with all biologic markers of tumor aggressiveness, including the triple-negative breast cancer subtype (P < 0.0001). In contrast, a high baseline BF was associated only with obesity (P = 0.002). The change in SUVmax (mean, -44.6% ± 27.4%) varied depending on the Scarff-Bloom-Richardson grade, overexpression of human epidermal growth factor receptor 2 (HER2-positive), and lack of hormone receptor expression (P = 0.04, P < 0.001, and P = 0.01, respectively). BF (mean change, -26.9% ± 54.3%) showed a drastic reduction only in HER2-positive subtypes (-58.7% ± 30.0%), supporting the antiangiogenic effect of trastuzumab. Changes in SUVmax outperformed changes in BF for predicting pCR in all tumor subtypes: the areas under the curve for change in SUVmax were 0.82, 0.65, and 0.90 in the triple-negative, HER2-positive, and luminal subtypes, respectively. Conclusion: Of the two biologic hallmarks of cancer evaluated in this study, a reduction in tumor glucose metabolism was more accurate than a reduction in tumor BF for predicting pCR in the different subtypes of breast cancer.
引用
- Humbert O, Lasserre M, Bertaut A, et al. Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response. J Nucl Med. 2018. PMID: 29439010. doi:10.2967/jnumed.117.203075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。